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Abstract
Introduction: Major hyperferritinemia is a rare feature in clinical laboratories associated with a wide variety of disorders, including hemophago-
cytic lymphohistiocytosis (HLH). The diagnosis of HLH is based on clinical and biological criteria, such as those proposed by the Histiocyte Society. 
However, several of these criteria are not relevant in the specific setting of hematologic malignancies.
Materials and methods: A 69-year-old male was treated for an acute myeloid leukaemia. On day 15 after the start of chemotherapy, he developed 
severe sepsis with high fever, low blood pressure and hepatosplenomegaly. 
Results: Blood tests were marked by extreme hyperferritinemia (191,000 µg/L, reference range: 26-388 µg/L) with increased C-reactive protein 
(87.0 mg/L) and procalcitonin (1.94 µg/L) and aspartate aminotransferase (499 U/L 37 °C) in the setting of chemotherapy-induced aplasia. This unu-
sual extreme ferritinemia led to suspect HLH triggered by an invasive infection. Under intensive treatment, the clinical status improved and ferritin 
levels significantly decreased. 
Conclusions: The diagnosis of HLH is usually based on clinical and biological criteria, mainly fever, splenomegaly, cytopenias, hypertriglyceridemia, 
hypofibrinogenemia, hemophagocytosis and hyperferritinemia. In this patient, the diagnosis of HLH was challenging because several criteria, such 
as hypertriglyceridemia, hemophagocytosis and hypofibrinogenemia, were absent. In addition, some criteria of HLH are not relevant in the setting 
of hematologic malignancy, in which fever, splenomegaly, cytopenias and elevated lactate dehydrogenase are commonly observed independently 
of HLH. This unusual case of extremely high ferritinemia emphasizes the important weight of the ferritin level for the diagnosis of HLH in adult pati-
ents in the setting of hematologic malignancies. 
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Ferritin is an iron storage protein which plays a major 
role in the regulation of iron metabolism (1). Ferritine-
mia is routinely used to assess iron status. While mild 
hyperferritinemia is commonly observed in inflamma-
tory diseases and alcoholism, major hyperferritinemia 
is much more unusual. Major hyperferritinemia > 
50,000 µg/L was recently reported to be associated 
with a wide variety of disorders such as renal failure, 
hepatocellular injury, infection, hematologic malignan-
cy, rheumatologic disorders, iron overload, haemolytic 
anaemia and hemophagocytic lymphohistiocytosis 
(HLH) (2–4). HLH is a rare but life-threatening condi-
tion, caused by genetic mutations (familial HLH) or sec-
ondary to infections, malignancies or autoimmune dis-
eases (acquired HLH) (5,6). HLH is characterized by an 
uncontrolled hyper activation of the immune system, 
leading to organ damages (6). Extremely high levels of 
ferritin may not only be a reflection of inflammation in 
HLH, but may also play a role in the pathogenesis of 
the disease (2). A prompt and accurate diagnosis of 
HLH is crucial to start treatment as soon as possible 
and therefore to enhance chances of survival. To date, 
the diagnosis of HLH is based on clinical and biological 
criteria, such as those proposed by the Histiocyte Soci-
ety in their paediatric HLH-2004 diagnostic guidelines 
(7). These latter specify that at least 5 of the 8 following 
criteria are required for the diagnosis of HLH: fever, 
splenomegaly, cytopenia affecting 2 lineages (Hb < 90 
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g/L, Plt < 100 x 109/L, neutrophil count < 1.0 x 109/L ), 
hypertriglyceridemia and/or hypofibrinogenemia (> 
3.0 mmol/L and < 1.5 g/L, respectively), hemophago-
cytosis (in the bone marrow aspirate, spleen or lymph 
node), hyperferritinemia > 500 µg/L, impaired NK cell 
function and sIL2R > 2400  U/mL (7). But, in the setting 
of hematologic malignancies, several important crite-
ria for the diagnosis of HLH such as cytopenias, fever or 
splenomegaly may be commonly found as conse-
quences of the disease or treatments in the absence of 
HLH. Here, we report a case of major hyperferritinemia, 
which is original because of the extremely high ferritin 
level, and because it emphasizes to what extent major 
hyperferritinemia is useful for the diagnosis of HLH in 
the specific setting of hematologic malignancies.
Materials and methods
Subject
A 69-year-old male with no significant medical history 
was admitted for chest pain to the emergency depart-
ment of the University Hospital Centre Dijon-Burgundy 
(France). Routine biochemical and haematological 
blood tests were performed. Informed consent was 
obtained from the patient, and all procedures were in 
accordance with our institutional Ethics Committee 
and with the Declaration of Helsinki.
Methods
Ferritin, electrolytes, aspartate aminotransferase (AST), 
alanine aminotransferase (ALT), triglycerides, C-reac-
tive protein (CRP) and troponin Ic were measured on 
Dimension Vista analyser (Siemens, Eschborn, Germa-
ny) with dedicated reagents. The ferritin assay on Di-
mension Vista is a sandwich chemiluminescent immu-
noassay with calibrators traceable to the WHO 3rd IS 
94/572 standard. Complete blood cell count and hae-
mostasis tests were performed on Sysmex XN-9000 
platform (Sysmex Corporation GmbH, Hamburg, Ger-
many) and STA-R (Diagnostica Stago, Asnieres-sur-
Seine, France), respectively. Procalcitonin was obtained 
with the Brahms Kryptor analyser (Thermo Scientific, 
Hennigsdorf, Germany). All instructions of manufactur-
ers were followed. 
Results
Blood tests allowed to exclude myocardial infarction 
based on negative troponin I (i.e. < 0.02 µg/L), con-
firmed 6 hours later. Upon admission, laboratory inves-
tigations revealed anaemia (haemoglobin (Hb) = 87 
g/L), thrombocytopenia (platelets (Plt) = 80 x 109/L) 
and 20% blast cells in the white blood cell (WBC) count 
(9.3 x 109 L). The bone marrow aspirate contained 22% 
blasts (99% CD33 positive cells). All biological investi-
gations taken together led to the diagnosis of acute 
myeloid leukaemia (AML) M5 with a mutation in the 
nucleophosmin (NPM1) gene. Then, the patient was 
rapidly started (day 0) on induction therapy with cyta-
rabine, daunorubicin and anti-CD33 monoclonal anti-
body. In addition, posaconazole was administered to 
prevent invasive fungal infection in this patient colo-
nized with Candida albicans. The chemotherapy-in-
duced aplasia started on day 5 with Hb = 91 g/L, neu-
trophils = 0.37 x 109/L and Plt = 21 x 109/L.
On day 15, the patient developed signs of severe sepsis 
with prolonged high fever > 39 °C and episodes of low 
blood pressure, associated with hepatosplenomegaly. 
The clinical and laboratory features on day 15 are 
shown in Table 1. These laboratory test results were 
mainly marked by extremely high ferritinemia around 
191,000 µg/L (reference range: 26 - 388 µg/L), con-
firmed the following day (compared with 1140 µg/L 
upon admission) associated with increased inflamma-
tory markers and transaminases. HLH was primarily 
suspected considering the prolonged fever, hepatos-
plenomegaly and major hyperferritinemia in a context 
of predisposing underlying diseases, i.e. both AML and 
infection. It was suspected that an invasive fungal in-
fection had triggered HLH in the light of repeated in-
creases in β-D-glucan and procalcitonin levels, despite 
negative blood cultures in this patient preventively 
treated with posaconazole. Considering the life-threat-
ening presentation, an intensive treatment was imme-
diately started with support measures, and antifungal 
and antibiotic drugs, leading to a clinical improvement 
in the following days without use of steroids or etopo-
side. 
On day 19, levels of inflammatory markers, CRP (21.4 
mg/L) and procalcitonin (0.50 µg/L), had significantly 
decreased. On day 20, the patient’s fever and aplasia 
had resolved (neutrophils = 1.4 x 109/L, Hb = 94 g/L), 
but the severe thrombocytopenia persisted (Plt = 15 x 
109/L). This, however, was successfully treated with in-
travenous gamma globulin over the course of 4 days, 
suggesting that it was probably a post infection auto-
immune condition. On day 23, hepatic cytolysis mark-
ers had fallen with 87 and 201 U/L for AST and ALT, re-
spectively. Ferritin levels gradually decreased (33,900 
and 4280 µg/L on days 22 and 34, respectively). 
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Features Values Reference range Units
Clinical features
Weight 75 - kg
Height 1.72 - m
Fever*† Present Absent -
Organomegaly*† Present Absent -
Predisposing underlying disease* Present Absent -
Biochemical features
Sodium 138 135–145 mmol/L
Creatinine 90 59–104 µmol/L
Estimated glomerular filtration rate 63 > 90 mL/min/1.73m2
AST 499 (87 on day 23) 15–37 U/L 37 °C
ALT 246 (201 on day 23) 16–63 U/L 37 °C
Ferritin*† 191,000 (33,900 on day 22; 4280 on day 34) 26–388 µg/L
Lactate dehydrogenase* NP 132–252 U/L 37 °C
Triglycerides 1.69 < 1.70 mmol/L
CRP 87.0 (21.4 on day 19) < 3.2 mg/L
Procalcitonin 1.94 (0.50 on day 19) < 0.10 µg/L
Haematological features
Haemoglobin* 95 130–170 g/L
Platelets*† 18 (15 on day 20) 150–450 x109/L
White blood cells* 1.0 4.0–10.0 x109/L
Neutrophils† 0.13 (1.4 on day 20) 1.80–7.50 x109/L
Eosinophils 0.0 0–0.8 x109/L
Basophils 0.0 0–0.2 x109/L
Lymphocytes 0.48 1.00–4.00 x109/L
Hyperbasophilic lymphocytes 0.02 Absent x109/L
Monocytes 0.0 0.2–1.0 x109/L
Immature monocytes 0.37 Absent x109/L
Hemophagocytosis* in bone marrow 
aspirate Absent Absent -
Coagulation profile
Prothrombin time 63 > 70 %
APTT 1.47 Ratio < 1.20 sec
Fibrinogen 4.5 2.0–4.0 g/L
D-dimer > 4000 < 500 ng/mL
Lupus anticoagulant negative negative
Microbiological features
(1→3)-β-D-glucan 70 (and 151 on day 16) 2 consecutive results < 60 pg/mL
Hemocultures negative negative -
*expert-based criteria for the diagnosis of HLH (10)
†positive (present) criteria for the diagnosis of HLH according to the HLH-2004 diagnostic guidelines (7). 
CRP – C-reactive protein, AST – aspartate aminotransferase, ALT – alanine aminotransferase, APTT – activated partial thrombo plastin 
time, NP – not performed.
Table 1. Clinical and laboratory features (on day 15 after the start of induction therapy). 
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Discussion
The Histiocyte Society proposed that at least 5 of the 8 
following criteria are required for the diagnosis of HLH: 
fever, splenomegaly, cytopenia affecting 2 lineages 
(Hb < 90 g/L, Plt < 100 x109/L, neutrophil count < 1.0 x 
109/L), hypertriglyceridemia and/or hypofibrinogene-
mia (> 3.0 mmol/L and < 1.5 g/L, respectively), he-
mophagocytosis (in the bone marrow aspirate, spleen 
or lymph node), hyperferritinemia > 500 µg/L, im-
paired NK cell function and sIL2R > 2400 U/mL (7). Our 
patient met three of these criteria namely fever, sple-
nomegaly and hyperferritinemia, which are reported 
in 96, 73 and 100% of HLH cases, respectively (3). Obvi-
ously, the presence of predisposing underlying disease 
in the patient, i.e. both malignancy and infection, 
which are reported in 49 and 33% of HLH cases, respec-
tively, was an important feature for the diagnosis of ac-
quired HLH (3).
The diagnosis of HLH was challenging in this patient 
for several reasons. First, several laboratory criteria 
from the HLH-2004 diagnostic guidelines were absent 
(7). In particular, there were no signs of hemophagocy-
tosis in the bone marrow aspirate, no hypertriglyceri-
demia ≥ 3.0 mmol/L and no hypofibrinogenemia ≤ 1.5 
g/L, even though they are reported in 85, 69 and 48% 
of cases of HLH, respectively (5). Second, other difficul-
ties were due to limitations of the diagnostic criteria 
themselves. For instance, assessment of NK cell func-
tion, sIL2R and glycosylated ferritin are not available in 
routine practice, or results are returned late (8). In our 
case, these specialized tests could not be performed 
because not available in our facilities, but it reflects the 
everyday practice for most institutions. Moreover, 
there are no consensual validated diagnostic guide-
lines for adult HLH to date, thus leading to the use of 
paediatric criteria, like those from the HLH-2004 guide-
lines (7). Other criteria for HLH in adults were recently 
developed, but in the specific population of systemic 
juvenile idiopathic arthritis (9). Last but not least, an-
other difficulty to diagnose HLH in our case was inher-
ent to the specific context of hematologic malignancy. 
Indeed, several diagnostic criteria, such as cytopenias, 
fever, splenomegaly and elevated lactate dehydroge-
nase, are commonly found in this setting independent-
ly of HLH. Therefore, these criteria cannot be consid-
ered relevant in this context, although cytopenias, fe-
ver, organomegaly and elevated lactate dehydroge-
nase were considered important for the positive diag-
nosis of HLH for 100, 96, 92 and 75% of members of a 
panel of experts, respectively (10). Cytopenia affecting 
at least one lineage was even considered an absolute 
requirement for 89% of them (10). 
In view of these difficulties, fever, marrow hemophago-
cytosis and very high ferritin level are considered as 
the cornerstones of the diagnosis in patients with AML 
(11). In our case, the high ferritin level appeared, in fact, 
as a preponderant criterion for the diagnosis of HLH. 
Elevated ferritinemia is a well-known hallmark of HLH. 
A recent paper reported that mean ferritinemia on the 
presentation of HLH was 5316 µg/L (ranging from 321 
to 9100 µg/L (3)), which is consistent with the mean val-
ue of 5140 µg/L reported in another adult cohort (12). 
Ferritinemia is a sensitive biomarker for the diagnosis 
of HLH. For instance, sensitivity was evaluated at 90-
100 and 71% for thresholds of ferritinemia of 500 µg/L 
and 1000 µg/L, respectively (3,7). In other words, nor-
mal ferritinemia has an excellent negative predictive 
value for the diagnosis of HLH. On the other hand, the 
positive predictive value of major hyperferritinemia is a 
matter of debate. Schram et al. recently reported that 
major ferritinemia > 50,000 µg/L was associated with 
HLH in only 17% of cases (13). In contrast, another 
group considered that an extremely high ferritin level 
was predictive of HLH, because it was observed in very 
few disorders, such as HLH and adult-onset Still’s dis-
ease (2). Likewise, Allen et al. found a specificity of 96% 
for HLH using a ferritin threshold of 10,000 µg/L (14). 
However, this latter study was conducted in a paediat-
ric population, in which the spectrum of underlying 
disorders is quite different from than in adult popula-
tions. Either way, among all disorders associated with 
major hyperferritinemia, the likelihood of a diagnosis 
of HLH seems to be higher for very high ferritin levels 
(4,13). Indeed, Saeed et al. recently reported that, 
among all causes of hyperferritinemia, the specificity 
and the positive likelihood ratio for a diagnosis of HLH 
increased in parallel of the ferritin cut off in adult pa-
tients (15).
An HScore was recently developed to estimate the in-
dividual risk of having HLH (8). This HScore takes into 
account three clinical and five biological weighted vari-
ables, which are easily available, i.e. triglyceridemia, 
AST, fibrinogenemia, cytopenias and ferritinemia. The 
best cut off value of the HScore was estimated at 169, 
corresponding to a sensitivity of 93% and a specificity 
of 86% for HLH, with 90% of patients accurately classi-
fied (8). In our patient, we aimed to calculate the 
HScore based on features on day 15 (algorithm availa-
ble online http://saintantoine.aphp.fr/score/), by con-
sidering values of haemoglobin, platelets and WBC as 
unknown in the model because there are not relevant 
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in the context of chemotherapy-induced aplasia. In this 
manner, the HScore for our patient was 202, corre-
sponding to an 89% probability of a diagnosis of HLH. 
By introducing ferritinemia lower than 2000 µg/L 
(threshold proposed by the algorithm) into the model, 
the HScore fell very significantly from 202 to 152, as did 
the probability of HLH from 89 to 28 %. This calculation 
emphasizes the important weight of the ferritin level 
for the diagnosis of HLH in the context in which hema-
tologic parameters are not relevant.
In conclusion, this unusual case of extremely high fer-
ritinemia highlights the preponderant contribution of 
an extreme ferritin level to the diagnosis of HLH in 
adult patients in the setting of AML.
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